|
Aug 1
|
GMAB vs. ACAD: Which Stock Is the Better Value Option?
|
|
Jul 29
|
Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More
|
|
Jul 28
|
TD Cowen Maintains a Hold on Genmab A/S (GMAB)
|
|
Jul 26
|
Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
|
|
Jul 25
|
Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook
|
|
Jul 24
|
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
|
|
Jul 22
|
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
|
|
Jul 22
|
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
|
|
Jul 1
|
Genmab Announces Changes to its Executive Committee
|
|
Apr 10
|
Genmab A/S Share Capital Reduction
|
|
Apr 7
|
Transactions In Connection with Share Buy-back Program
|
|
Feb 20
|
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
|
|
Feb 19
|
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
|
|
Jan 3
|
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Oct 9
|
Genmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
|
Oct 8
|
GMAB or INCY: Which Is the Better Value Stock Right Now?
|
|
Oct 8
|
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
|
|
Jul 29
|
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
|
|
Jul 25
|
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Jul 8
|
GMAB vs. TECH: Which Stock Is the Better Value Option?
|